Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
about
Novel immunotherapiesImmunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions.Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells.Myeloma proteins as tumor-specific transplantation antigensCell-bound myeloma proteins on the surface of myeloma cells: potential targets for the immune systemSpecific suppression of the antibody response by antibodies to receptors.Demonstration of an idiotypic antigen on a monoclonal cold agglutinin and on its isolated heavy and light chains.Binding to idiotypic determinants of large proportions of thymus-derived lymphocytes in idiotypically suppressed mice.Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes.Localization of idiotypic antigenic determinants in the Fv region of murine myeloma protein MOPC-315.Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphomaRegulation of immune response by autogenous antibody against receptor.Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.Immunotherapy in multiple myeloma: current strategies and future prospects.Dendritic cell-based immunotherapy in multiple myeloma.Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.DNA vaccines, electroporation and their applications in cancer treatmentDistribution of a cross-reactive idiotypic specificity in inbred strains of miceHomogenous rabbit 7S anti-IgG with antibody specificity for peptidoglycan.Clonal nature of the immune response to phosphorylcholine. I. Specificity, class, and idiotype of phosphorylcholine-binding receptors on lymphoid cells.Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 miceA small hypervariable segment in the variable domain of an immunoglobulin light chain stimulates formation of anti-idiotypic suppressor T cells.Production of auto-anti-idiotypic antibody during the normal immune response to TNP-ficoll. I. Occurrence in AKR/J and BALB/c mice of hapten-augmentable, anti-TNP plaque-forming cells and their accelerated appearance in recipients of immune spleen cT lymphocyte-mediated suppression of myeloma function in vitro. IV. Generation of effector suppressor cells specific for myeloma idiotypes.Genetic basis for expression of the idiotypic network. One unique Ig VH germline gene accounts for the major family of Ab1 and Ab3 (Ab1') antibodies of the GAT system.Antibodies to idiotypes of isologous immunoglobulinsTherapeutic lymphoma vaccines: importance of T-cell immunity.BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.Idiotypic cascades associated with the CD4-HIV gp120 interaction: principles for idiotype-based vaccines.Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.Reaction of anti-idiotypic antibody with the hapten-binding site of a myeloma protein.Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.Prospects for the treatment of B cell tumors using idiotypic vaccination.A Nonadjuvanted IgG2a Monoclonal Antibody against Nucleosomes Elicits Potent T Cell-Dependent, Idiotype-Specific IgG1 Responses and Glomerular IgG1/IgG2a Deposits in Normal Mice.B-cell tolerance to the B-cell receptor variable regions.Suppression of MOPC-167 growth in vivo by immunization against the idiotype of the MOPC-167 myeloma protein.Processing and presentation of idiotypes to MHC-restricted T cells.Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II moleculeSomatic point mutations in unrearranged immunoglobulin gene segments encoding the variable region of lambda light chainsTargeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.
P2860
Q33822677-18800565-5C2D-44BF-9043-B5B84CD06B4BQ34064690-FC974C5A-4CAF-4A14-A44C-A9706F6E9E46Q34428944-8D025895-0E7B-4591-BD9A-946228BC4DEDQ34709927-C59A091A-0B2B-4E90-9443-857B0B59FD83Q34722592-C62CFE06-98AB-4F38-9EA6-9E2BEA84DD84Q34730202-CF73150E-A41A-4211-864F-E7FB662A82F1Q35002950-A58B6F6D-CFF1-4017-B747-02228F6A55CAQ35027811-45E1988A-A8CB-47E4-89AD-F1E512BEC36BQ35082019-095F9CC1-6FFD-4C91-A30E-5D20663E6FBBQ35104724-5D05DB0A-60A6-432F-A717-2767EB50766BQ35114545-5A7CA076-640A-49D5-BF6C-1D3A32E5DD6CQ35121413-B5B46F24-E1C4-47E1-A606-9B91F866354BQ35144751-73806946-90D2-4CAE-9A44-DE3F79E2087BQ35194182-B2EDAE1D-460D-45C6-BC44-5AE3A3C6BE21Q35665926-E20E5388-B814-419C-8370-3C72B38D54EBQ35848862-5D0F1F3B-BEE3-4AF7-8B95-DFB1BDB22356Q36256459-6327A1B2-EDCE-4741-B68B-47DFC02467F5Q36271815-DDBA14AC-41EE-4563-925C-03671EEF0670Q36272612-5690CF71-C016-47C6-8726-E357536E16B8Q36272875-0038F480-34A8-40AE-B3BA-AC8E72452B72Q36273765-8545C213-BFF8-4C8F-8116-9882FD4E7D9EQ36311069-5108B674-3C16-493F-A18A-6514E140EA93Q36342648-53219BB9-5EB0-4B12-8EDD-A1198C79D749Q36346333-6F351B3C-E5DD-40D6-8408-CED6575A64C3Q36351691-FA8AC5DE-D958-4BA3-A071-5E0DC60C9051Q36358144-A9716A07-376E-4F1C-A067-C891425955E1Q36530231-0636F716-FE7F-48D1-BB2E-B83657C76CABQ36675461-07661F1C-426D-4075-9DA8-A8FF276AFCF6Q36708986-25220E9B-37A7-46C7-A7AB-49EBC8EE94F3Q37305644-03E80DB9-73A9-4D46-A666-3F2DB80536CFQ37494715-7498A433-1100-492E-A70B-B89A516B8878Q38246919-7383ADCD-2B65-42F5-8BBD-053434AFC7DBQ38246920-085EAC41-1CD7-4065-B626-D75D3DC7CE54Q38737661-7B5D86E6-F6EA-41DF-BEAA-3AA25E3895BFQ39128184-F6639C0F-DC43-4646-BC69-24172766AB51Q40735327-C9790257-9726-4D6B-9810-7190B4DF174EQ40808121-83A766DD-C5F4-475D-B15A-AA0A0626C5F2Q40818236-D4A7F1EE-A853-47BF-B5E4-489BF8E1E5A6Q41337845-5FA8AB62-8EC8-4648-97FA-824E355E6A2FQ41648531-ED065898-0093-4A4A-B895-254B90D81B6C
P2860
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1971
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
@en
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
@nl
type
label
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
@en
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
@nl
prefLabel
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
@en
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
@nl
P2860
P356
P1476
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.
@en
P2093
P2860
P304
P356
10.1073/PNAS.68.12.3130
P407
P577
1971-12-01T00:00:00Z